C. Robert Horsburgh - Concepedia

Author

C. Robert Horsburgh

Also Known As

C R Horsburgh, C Robert Horsburgh, C Robert Horsburgh Jr, C Robert Horsburgh, Jr., C. Horsburgh, C. R. HORSBURGH, C. R. Horsburgh, C. R. Horsburgh Jr, C. R. Horsburgh Jr., C. R. Horsburgh,

523

Publications

29.8K

Citations

H-Index

172

Concepts

All Affiliations

Boston University Centers for Disease Control and Prevention Boston Medical Center Emory University Harvard University

About

C. Robert Horsburgh is an author at Boston University specializing in medicine, hiv, and tuberculosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	70	5.9K
2	Public Health	18	25	1.9K
3	Health Sciences	9	9	685
4	Social Sciences	8	8	359
5	Education	1	1	33

C. Robert Horsburgh

209

Publications

15.7K

Citations

H-Index

Page 1

	Year	Citations
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection Timothy R. Sterling, Margarita E. Villarino, Andrey Borisov, New England Journal of Medicine	2011	946
Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin Marian Goble, Michael D. Iseman, Lorie A. Madsen, New England Journal of Medicine	1993	705
Priorities for the Treatment of Latent Tuberculosis Infection in the United States C. Robert Horsburgh New England Journal of Medicine	2004	645
Accelerated course of human immunodeficiency virus infection after tuberculosis. Christopher Whalen, C. Robert Horsburgh, D. Hom, American Journal of Respiratory and Critical Care Medicine Pulmonary TuberculosisEpidemiologyBaseline Cd4+ CountTreatment And PreventionHuman Retrovirus	1995	534
The Epidemiology of Disseminated Nontuberculous Mycobacterial Infection in the Acquired Immunodeficiency Syndrome (AIDS) C. Robert Horsburgh, Richard M. Selik American Review of Respiratory Disease Aids CasesVirus EpidemiologyImmunologyViral DynamicM. Avium Complex	1989	457
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari Mase, Giovanni Battista Migliori, American Journal of Respiratory and Critical Care Medicine	2019	430
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Debra Benator, Mondira Bhattacharya, Lorna Bozeman, The Lancet Pulmonary TuberculosisTreatment And PreventionMedicineRandomised Clinical TrialWeek Versus Rifampicin	2002	408
The resurgence of tuberculosis: is your laboratory ready? Fred C. Tenover, Jack T. Crawford, Robin Huebner, Journal of Clinical Microbiology Pulmonary TuberculosisTuberculosis PreventionLaboratory MedicineTuberculosisTuberculosis Diagnostics	1993	376
Evaluation of exposure-specific risks from two independent samples: A simulation study William M. Reichmann, David Gagnon, C. Robert Horsburgh, BMC Medical Research Methodology	2011	309
DURATION OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION BEFORE DETECTION OF ANTIBODY C. Robert Horsburgh, Janine Jason, IraM. Longini, The Lancet Primary ImmunodeficiencyHuman RetrovirusImmunodeficienciesImmunologySerologic Testing	1989	291

Page 1